Substantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality tamoxifen, ovarian ablation or suppression, or chemotherapy. To determine whether additional benefits exist with combined treatment, the Adjuvant Breast Cancer (ABC) Trials were undertaken.
ARTICLE
In 1992, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) systematic overview of randomized trials (1) reported that chemotherapy and ovarian ablation or suppression were of similar efficacy when given as single-modality treatments in preand perimenopausal women with early breast cancer. Ovarian ablation and suppression were defined as ablation of ovarian function by oophorectomy or irradiation of the ovaries or as suppression of ovarian function by treatment with luteinizing hormone -releasing hormone (LH-RH) agonists. In addition, the EBCTCG overview demonstrated that the effects of prolonged tamoxifen treatment (>2 years) in young women (aged <50 years) were consistent with the benefit that was already recognized for older women. Subsequently, prolonged tamoxifen (usually 5 years) became an alternative or adjunct to chemotherapy or ovarian ablation or suppression.
The EBCTCG overview included trials conducted in the era before the introduction of routine testing of estrogen receptor (ER) status. The overview did not include information on the addition of ovarian ablation or suppression to tamoxifen and included data on only 939 patients to evaluate ovarian ablation or suppression in addition to chemotherapy. Among patients who did not receive other systemic therapy, benefi ts of ovarian ablation or suppression were clear -30% reduction in the annual odds of recurrence and a 28% reduction in the annual odds of death from any cause. However, in those treated with chemotherapy, a suggestion of benefi t for ovarian ablation or suppression was also observed, although the results did not reach statistical signifi cance (21% reduction in the annual odds of recurrence and a 19% reduction in the annual odds of death from any cause). These data prompted the question of whether ovarian ablation or suppres sion added to elective tamoxifen would lead to worthwhile survival gains, including in patients with retained or recovered ovarian function who had been prescribed cytotoxic chemotherapy. Because ovarian ablation or suppression as a sole systemic modality is associated with considerable side effects, it was recognized that potential survival gains from its combination with tamoxifen would need to outweigh any corresponding increase in adverse effects.
In the early 1990s, ovarian ablation or suppression was commonly achieved via surgery or radiation therapy, although the use of LH-RH agonists was emerging. Additionally, at that time in the United Kingdom, testing for ER status was not routinely available, at least in part, because the EBCTCG overview at that time suggested a benefi t for tamoxifen in both ER-positive (+) and ERnegative ( − ) breast cancer.
Therefore, in late 1992, the Adjuvant Breast Cancer (ABC) Trials were initiated to assess long-term outcomes, particularly overall survival, of combined modality therapy for women with early breast cancer. The ABC Chemotherapy (CT) Trial compared combination treatment with tamoxifen and chemotherapy with prolonged tamoxifen only, with or without elective ovarian ablation or suppression (in pre-and perimenopausal women). Here we present the results of the ABC Ovarian Ablation or Suppression (OAS) Trial, which assessed the addition of ovarian ablation or suppression to prolonged tamoxifen (with or without elective chemotherapy).
Subjects and Methods

Design
The ABC (OAS) Trial aimed to identify the added benefits of prescribing ovarian ablation or suppression in addition to prolonged tamoxifen or prolonged tamoxifen accompanied by chemotherapy in pre-and perimenopausal women with early breast cancer. All patients were scheduled to receive prolonged tamoxifen [5 years unless patient was entered into the Adjuvant Tamoxifen Longer Against Shorter (2) or Does Adjuvant Tamoxifen Treatment Offer More? (3) trials of tamoxifen duration] and were randomly assigned to ovarian ablation or suppression. Use of chemotherapy was at the clinician's discretion (including the option for the patient to be entered into the ABC [CT] Trial), but with a requirement to declare such treatment before random assignment into the ABC (OAS) Trial. A total of 281 patients were entered into both the ABC (CT) and ABC (OAS) Trials.
The primary endpoint for this study was overall survival, based on all-cause mortality. Secondary endpoints were breast cancerspecifi c mortality (not reported here) and relapse-free survival.
Eligibility
Eligible patients were women who were pre-or perimenopausal with histologically confirmed early-stage operable (T1-3a N0-1 M0) invasive breast cancer. Women were defined as pre-or perimenopausal if their last menstrual period had occurred within the 12 months preceding breast diagnostic surgery. Patients could have had no previous malignancy (except cervical cancer in situ or basal cell carcinoma) and no previous systemic therapy for their current breast cancer and had to be available for follow-up. The trial was open to recruitment from January 7, 1993 , to September 27, 2000 .
Evaluation of Estrogen Receptor Status
For patients who had unknown ER status at randomization, retrospective testing of the ER has subsequently been carried out centrally on the majority of tumor samples from women residing in the United Kingdom (and some non-UK women). Testing was carried out by using immunohistochemistry using paraffinembedded tissue, as described previously (4) . Alternatively, results were obtained from local hospitals where information on ER status is now available.
Treatment
The method of achieving ovarian ablation or suppression was at the clinician's discretion but was to be according to center policy and declared before randomization (thus avoiding bias). Specific recommendations for radiation ablation and LH-RH agonists were defined in the protocol. For radiation-induced menopause, 1600 cGy in four fractions was to be delivered to the midplane by the anteroposterior fields of the pelvis after ultrasound localization of the ovaries. If LH-RH agonists were to be used, goserelin (Zoladex) at 3.6 mg or leuprorelin acetate (Prostap SR) at 3.75 mg was recommended every 28 days for at least 2 years.
CONTEXT AND CAVEATS
Prior knowledge
Women with early-stage breast cancer have improved outcomes after treatment with either tamoxifen, ovarian suppression or ablation, or chemotherapy.
Study design
Randomized controlled phase III clinical trial of tamoxifen treatment in combination with chemotherapy among premenopausal women who did or did not undergo ovarian ablation or suppression.
Contributions
Rates of relapse-free survival and overall survival were similar among women who underwent ovarian ablation or suppression and those who did not.
Implications
Ovarian ablation or suppression may not improve outcomes of combined tamoxifen and chemotherapy treatment for premenopausal women with early-stage breast cancer.
Limitations
Patients were treated with tamoxifen and ovarian ablation or suppression regardless of tumor estrogen receptor status. The chemotherapy regimen used may have had effects similar to those of ovarian ablation or suppression, possibly masking the effects of the latter. Surgery and radiotherapy were carried out according to local policy but within protocol-specifi ed recommendations. Tamoxifen (20 mg/day) was prescribed for a minimum of 5 years in all patients starting within 4 weeks of primary surgery and concurrently with chemotherapy, if given. Chemotherapy and ovarian ablation or suppression were scheduled according to local practice. Random assignment to the ABC (OAS) Trial was permitted before chemotherapy commenced or while chemotherapy was ongoing. Of the 1529 patients with known date of fi rst chemotherapy cycle, 637 (41.7%) were randomly assigned before commencing chemotherapy and 685 (44.8%) within 3 months of commencing chemotherapy. The remaining 207 (13.5%) of patients were randomly assigned 3 or more months after commencing chemotherapy. No assessment or selection based on postchemotherapy menopausal status was required because it was recognized that a proportion of patients resume substantial ovarian estrogen production over the course of the fi rst year post-chemotherapy. 
Ethics and Governance
Data Collection and Follow-up
Patients were followed up annually via their participating hospital. All UK patients were flagged through the Office for National Statistics. Case report forms included a minimum defined dataset required to assess the main endpoints and a summary assessment of treatment compliance. Analysis was based on follow-up received by the trials units to June 30, 2004. Annual follow-up continues for all patients who are available for follow-up.
Relapses were diagnosed according to local practice. Local relapse was defi ned as cancer recurrence in or on the ipsilateral chest wall/breast, and all other sites were classifi ed as distant metastases.
No individual adverse event data was recorded because the toxicity profi le of trial treatments was considered to be well characterized; however, patient-reported symptomatology was recorded in the subset of patients in an associated Quality of Life study.
Quality of Life
The associated Quality of Life study was initiated in 1997 in 31 UK centers. All patients who entered the main trial from these centers were invited to participate in the Quality of Life study. Detailed methodology and results from this substudy will be published separately.
Statistical Analysis
Randomization was performed using randomly permuted blocks that were stratified by hospital and elective chemotherapy treatment. A 1 : 1 treatment allocation ratio was used. Among women who were to receive single-modality systemic therapy, 5-year overall survival was envisaged to be approximately 75% (1). If 5-year overall survival improved from 75% to 80% by the addition of ovarian ablation or suppression to prolonged tamoxifen (with or without chemotherapy), it was judged to be of clinical benefit. Based on this assumption and using a two-sided log-rank test ( ␣ = 0.05), 492 events were required for 80% power. It was estimated that approximately 2000 patients would need to be recruited to achieve this number of events.
Median follow-up was calculated using the reverse KaplanMeier estimator (5) . Analyses were according to the intention-totreat principle, included all randomly assigned patients, and were performed using STATA 8.0 (6). Overall survival was defi ned as time from date of random assignment to date of death. Relapsefree survival was defi ned as time from date of random assignment to date of fi rst recurrence or death from breast cancer with no known date of relapse. In the relapse-free survival analysis, patients were censored on the occasion of an intercurrent death. Cumulative survival curves were constructed as Kaplan -Meier time-to-event plots (5, 6) , with unadjusted comparisons between groups based on the log-rank test (two-sided). Cox regression models were used to estimate treatment effects, with adjustment for age, nodal status, and ER status. Proportionality of hazards was verifi ed according to Schoenfeld residuals. Estimates of treatment effect are presented as hazard ratios (HRs) with their associated 95% confi dence intervals (CIs), with ratios of less than 1.0 favoring the addition of ovarian ablation or suppression. Descriptive subgroup analyses by age with or without chemotherapy and ER status are presented as forest plots. Chi-square tests (for trend, if appropriate) were used to test for heterogeneity between subgroups. Results for the QL study are based on complete data available to 30 months. These longitudinal data were analyzed by general linear models for panel data using the generalized estimating equations approach (7) via the xtgee command in STATA 8.0. 
Results
Between January 7, 1993 , and September 27, 2000 , 2144 patients from 106 UK and 16 non-UK centers were entered into the ABC (OAS) Trial ( Fig. 1 ). Ten patients (seven allocated to ovarian ablation or suppression, three allocated to no ovarian ablation or suppression) were deemed to be ineligible for the following reasons: not early-stage breast cancer (n = 9) and previous other cancer (n = 1). Mean age of eligible patients was 43 (standard deviation = 5.7) years, 1298 (61%) had node-positive disease, 838 (39%) had confirmed ER+ tumors, 391 (18%) had ER − tumors, and 915 (43%) had tumors with unknown ER status. The two groups had well-balanced baseline characteristics ( Table 1 ) . Analysis was based on follow-up received by the trials units to June 30, 2004 . At this time, 11 152 women-years of follow-up had accrued. Median follow-up was 5.9 years (interquartile range [IQR] = 4.2 to 7.7). Completeness of follow-up was 80.0% (8) .
Nine hundred forty-two (88.6%) patients who were randomly assigned to ovarian ablation or suppression received allocated treatment ( Table 2 ). Compliance with treatment was lower among younger women (<35 years, 77.1%) than in older women and among women from non-UK centers (78.3%) compared with those from UK centers. Of patients who received ovarian ablation or suppression, 68.8% had radiation-induced menopause, 22.8% surgical ablation, and 8.4% LH-RH agonists. The majority of patients also received chemotherapy (78.5%). Among patients who received both treatments, 14% received ovarian ablation before chemotherapy, 37% received it during chemotherapy, and the remaining 49% received it after chemotherapy.
At the time of analysis, 1401 (65%) patients were no longer taking tamoxifen, of whom nine patients never took the drug. Median tamoxifen treatment duration (after censoring patients who stopped due to recurrence) was 5.0 years (IQR = 3.4 to 5.6 years).
To date, 445 deaths (21% of patients) and 596 recurrences have been reported ( Table 3 ). The unadjusted hazard ratio for relapse among patients in the ovarian ablation or suppression group was 0.95 (95% CI = 0.81 to 1.12, P = .56) ( Fig. 2 ) compared with those who did not undergo ovarian ablation or suppression. Five-year relapse-free survival was 73.7% (95% CI = 70.7% to 76.3%) in the ovarian ablation or suppression group compared with 72.8% (95% CI = 69.8% to 75.5%) in the group randomly assigned to no ovarian ablation or suppression, translating into an estimated absolute difference of 0.9% (95% CI = -3.1% to 4.9%). The unadjusted hazard ratio for death from any cause among patients in the ovarian ablation or suppression group compared with those in the no ovarian ablation or suppression group was 0.94 (95% CI = 0.78 to 1.13, P = .44) ( Fig. 3 ) . Five-year survival was 82.6% (95% CI = 80.0% to 84.9%) in the ovarian ablation or suppression group compared with 80.3% (95% CI = 77.5% to 82.9%) in the no-ovarian ablation or suppression group, for an estimated absolute difference of 2.3% (95% CI = -1.2% to 5.9%). There were very few intercurrent deaths, so the analysis of time to breast cancer death produces almost identical results to that of overall survival (data not shown).
Adjusting for prognostic factors (age, nodal status, and ER status) made little difference to the hazard ratios for either relapse-free or overall survival ( Table 4 ). As expected, there was a greater effect of ovarian ablation or suppression in women with ER+ tumors ( Fig. 4 ) , but there was no statistically signifi cant evidence of heterogeneity for either overall or relapse-free survival among any of the subgroups investigated. Adjusting for use of chemotherapy did not materially alter the estimate of effect (overall survival, HR = 0.94, P = .50; relapse-free survival, HR = 0.95, P = .56), and the interaction test was not statistically significant ( P = .68 for overall survival, P = .85 for relapse-free survival). In younger women (aged <40 years, n = 56) who did not receive chemotherapy, the group considered biologically to have the most to gain from ovarian ablation or suppression, there was a suggestion of a potentially useful clinical benefi t that was slightly greater if patients with tumors known to be ER − are excluded (increasing the proportion known to be ER+ from 32.1% to 40.9%). However, the above results are based on very small numbers (n = 56, Fig. 5 ; n = 44; Supplementary Fig. 1, available  online) .
Of the 1290 UK patients who were included in the ovarian ablation comparison, 246 (118 with ovarian ablation or suppression, 128 no ovarian ablation or suppression) agreed to take part in the Quality of Life substudy, and detailed results will be published elsewhere. In summary, patients who received ovarian ablation or suppression recorded more menopausal symptoms, e.g., night sweats ( P = .005), day sweats ( P <.001), and vaginal dryness ( P = .001) than patients who did not receive ovarian ablation or suppression. The effect of ovarian ablation or suppression on menopausal symptoms was seen in women receiving tamoxifen alone and in those who had received chemotherapy in addition to tamoxifen ( Fig. 6 ).
Discussion
In this trial, ovarian ablation or suppression did not add to the benefits of 5 years of tamoxifen treatment or to those of tamoxifen plus chemotherapy in terms of relapse-free survival or overall survival rates. No heterogeneity was observed across subgroups, although in the small subgroup of women younger than 40 years who did not receive chemotherapy, the data were consistent with a therapeutic benefit for ovarian ablation or suppression. However, this subgroup is too small to investigate any additional effect of ER status. Despite the apparent lack of therapeutic efficacy, the addition of ovarian ablation caused a considerable increase in acute and chronic side effects, e.g., hot flushes, sweats, and sleep disturbance.
Results of the EBCTCG overview (9) indicate that the benefi ts of ovarian ablation or suppression on relapse-free survival only become apparent after several years and that overall survival gains appear at 8 -10 years follow-up, but there is no evidence for the emergence of such effects in the ABC (OAS) Trial. The trial has collected more than 11 000 women-years of follow-up, but it is possible that benefi ts of ovarian ablation or suppression will emerge after further follow-up data have accrued.
The study has several potential limitations. First, tamoxifen and ovarian ablation or suppression were prescribed to patients regardless of ER status, whereas it is now clear that endocrine manipulation does not benefi t patients with ER − tumors. Although women with ER+ tumors would be considered for ovarian ablation today, we believe it appropriate to conduct the primary analysis in the intent-to-treat population. In addition, given that ER testing was not routinely assessed in these centers at the time the trial was conducted, there is little reason to suspect that women with tumors of unknown ER status were not representative of premenopausal breast cancer patients in general. Therefore, it can be assumed that Table 4 . Outcomes in the ovarian ablation or suppression group as compared with the no-ovarian ablation or suppression group *
Endpoint
Unadjusted hazard ratio (95% CI) P Adjusted hazard ratio (95% CI) P Relapse-free survival 0.95 (0.81 to 1.12) .56 0.98 (0.84 to 1.16) .84 Overall survival 0.94 (0.78 to 1.13) .44 0.97 (0.81 to 1.17) .79 * A Cox model including age (<40 or ≥ 40 years), nodal status (negative, 1 -3 positive nodes, ≥ 4 positive nodes, or missing), and ER status (positive, negative, or missing) was used to estimate the adjusted hazard ratios. CI = confidence interval; P values (two-sided) were calculated by using the log-rank test for the unadjusted hazard ratios and the Wald test from Cox regression for the adjusted hazard ratios. Years since random assignment approximately 65% of such patients will have had ER+ disease (10) . Exclusion of the large group of patients with unknown ER status would have detracted from the overall statistical power to test the underlying hypothesis. As expected, the estimate of effect for the group of women with tumors of unknown ER status appears to be an appropriate "average" of the effects in the ER+ and ER − subgroups. It is also noteworthy that ER status was unknown in the original trials that demonstrated an effect of ovarian ablation (9) . Nevertheless, no evidence was observed of benefi t for ovarian ablation or suppression in the subgroup of 838 patients known to be ER+ either ( Fig. 4 ) . A second limitation of the study relates to the probability of chemotherapy-induced castration in a majority of patients, which may have precluded the identifi cation of an ovarian ablation or suppression associated benefi t. The risk of chemotherapy-induced amenorrhea is directly related to age and varies with the chemotherapy regimen used and the total duration of chemotherapy (11, 12) . The average rates of amenorrhea for classic oral cyclophosphamide, methotrexate, and 5 fl uorouracil (CMF) and standard adiramycin and cytoxan are 68% and 43%, respectively, and 80% patients in the ABC (OAS) Trial received CMF. More than 50% women aged 40 years and older experience chemotherapyinduced amenorrhea, whereas this rate is less than 50% for women younger than 40 years. Even in the subgroup of women younger than 40 years who received chemotherapy, the majority of whom would have retained ovarian function, there appears to be no gain from ovarian ablation or suppression in combination with 5 years of tamoxifen treatment.
A third limitation is that chemotherapy was given concurrently with tamoxifen. This may have lessened the effi cacy of chemotherapy (13) , but it is highly unlikely to have masked an effect of ovarian ablation or suppression.
Finally, 11% of patients did not receive ovarian ablation as allocated. The most common reason was patient refusal after randomization, illustrating the diffi culties of performing trials of ovarian ablation. Noncompliance of this magnitude may result in a slight underestimation of the effect but would be unlikely to lead to a gross distortion of the results.
Several studies, like the ABC (OAS) Trial, have investigated the combination of other systemic therapies with ovarian ablation or suppression, whether tamoxifen or chemotherapy (14 -17) , or both (18, 19) . In the 2005 publication of the EBCTCG overview (9), ovarian ablation or suppression results were not presented according to concurrent tamoxifen use, but it is known that most of the ovarian ablation or suppression trials did not use tamoxifen. The Zoladex in Premenopausal Patients Trial (15) randomly assigned 2710 women (with no exclusion based on ER status) to goserelin for 2 years, tamoxifen for 2 years, and combined treatment or no further treatment in a 2 × 2 factorial design. Randomized treatment was given in addition to standard therapy following surgery, which could include radiotherapy and/or chemotherapy. In that study, 51% tumors were known to be ER+. Goserelin treatment was associated with a statistically signifi cant improvement in both event-free survival (HR = 0.80, 95% CI = 0.70 to 0.92) and overall survival (HR = 0.82, 95% CI = 0.67 to 0.99) (15) . Although no statistically signifi cant heterogeneity was observed, the effect of goserelin was greatest in patients with ER+ tumors who had not received chemotherapy (HR = 0.68, 95% CI = 0.51 to 0.90). The US Breast Intergroup Study 0142 (14) randomly assigned 345 women with ER+ tumors (target accrual 1684) to LH-RH agonist against a background of 5 years tamoxifen in node-negative premenopausal women not prescribed chemotherapy. All the patients were known to have ER+ tumors. No benefi t was observed for Other studies have examined the combination of chemotherapy and ovarian ablation or suppression. The International Breast Cancer Study Group (IBCSG) Trial VIII (17) randomly assigned 1063 pre-/perimenopausal patients with node-negative disease to goserelin for 2 years (six cycles of CMF or six cycles of CMF followed by goserelin). In that study (17) , 68% of patients were known to have ER+ tumors. In ER+ patients, there was no additional benefi t of adding goserelin to adjuvant chemotherapy (relative risk = 0.80, 95% CI = 0.54 to 1.19) . Two further studies (16, 18) did not fi nd a benefi t of adding ovarian ablation or suppression to chemotherapy. Kaufmann et al. (18) found no benefi t for goserelin following chemotherapy in 776 patients (HR = 0.92, 95% CI = 0.70 to 1.21). Although 60% of patients in this study had ER − tumors, subgroup analysis provided no evidence of benefi t in patients with ER+ tumors. Arriagada et al. (16) also found no benefi t of ovarian ablation or suppression in total or in subgroups based on ER status or in women who experienced amenorrhea following chemotherapy. However, a subgroup analysis of the IBCSG Trial VIII found that younger women ( ≤ 39 years) had a statistically signifi cant benefi t of combined treatment (CMF followed by goserelin) (HR = 0.34, 95% CI = 0.14 to 0.87) versus CMF alone (17) . This patient population is least likely to develop chemotherapy-induced ovarian failure.
Only one published study has randomly assigned all three potential adjuvant treatments. The INT-0101 study (19) enrolled 1504 node-positive premenopausal women with ER+ breast cancer to compare six cycles of oral combination chemotherapy with cyclophosphamide, doxorubicin, and fl uorouracil (CAF) versus CAF plus goserelin (CAFZ), versus CAFZ plus 5 years tamoxifen (CAFZT). After a median follow-up of 9.6 years, 9-year diseasefree survival was 57% for CAF, 60% for CAFZ, and 68% for CAFZT, and 9-year overall survival rates were 70%, 73%, and 76%, respectively (19) . Hypothesis-generating subgroup analyses suggest that women younger than 40 years of age at trial entry, those with premenopausal estradiol levels after chemotherapy, and those who retained menses after chemotherapy benefi ted the most from the addition of goserelin. A limitation to this trial is the lack of a cyclophosamide, doxorubicin, fl uorouracil, and tamoxifen arm.
The ABC (OAS) Trial adds new data to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation or suppression. The results suggest that ovarian ablation or suppression does not add to the benefi ts of prolonged tamoxifen in premenopausal women who are prescribed chemotherapy. However, we cannot rule out the possibility that a subgroup of premenopausal patients with ER+ tumors who did not receive chemotherapy or who did not become amenorrheic with chemotherapy, benefi ted from the addition of ovarian ablation or suppression. This question could not be tested in the ABC (OAS) Trial, but it will be addressed in the Suppression of Ovarian Function Trial coordinated by the IBCSG (20) . This trial will randomly assign patients with ER+ tumors who are still premenopausal following chemotherapy to tamoxifen alone, tamoxifen plus LH-RH agonists, or exemestane plus LH-RH agonists and should provide defi nitive results to inform future practice on the use of ovarian ablation or suppression in patients with hormone-sensitive early breast cancer. 
